News

Carolina Vision Center Opens Dry Eye Clinic to Help Frustrated Dry Eye Patients

Morrisville, N.C.,— October 14, 2011—TearScience, Inc., a privately-held medical device company, today announced that Fayetteville, North Carolina-based Carolina Vision Center, is the first eye care center in United States to commercially offer the LipiFlow Thermal Pulsation System, a breakthrough treatment for evaporative dry eye disease.  TearScience’s LipiFlow is designed to address meibomian gland dysfunction, allowing for the treatment of eyelid gland blockages during ...

MorrisvilLe, N.C.,—October 3, 2011—TearScience, Inc., a privately-held medical device company, today announced a $15M venture debt financing deal with Oxford Finance LLC and Silicon Valley Bank.  The financing supports TearScience’s commercialization efforts of its new, innovative solution for evaluating the eye’s natural tear film and treating evaporative dry eye disease.

“We are pleased to engage Oxford Finance and Silicon Valley Bank as our newest partners supporting our commercialization efforts,” said Nicole Wicker, vice president of finance for TearScience.  “Having ...

Morrisvile, N.C.,—August 15, 2011—TearScience, Inc., a privately-held medical device company, today announced that it has appointed Diethart Reichardt as senior vice president of the European region including Europe, Middle East and Africa. In this role, Reichardt will be responsible for sales, marketing, operations and customer service teams based in the European region as well as a distributor network in Africa and the Middle East. Reichardt will be based in Germany. TearScience’s advanced solutions are designed to help eye care physicians ...

TearScience to Begin Commercialization of LipiFlow In-office System in U.S.

MorrisvilLe, N.C.,—July 11, 2011—TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye. The clearance enables TearScience to market and sell LipiFlow to eye care physicians in the U.S. LipiFlow will be available immediately, but on a limited basis ...

TearScience’s New System Offers Breakthrough Treatment for Dry Eye Patients

Morrisvile, N.C.,— June 13, 2011—TearScience, Inc., a privately-held medical device company, announced that the Toronto-based Herzig Eye Institute, one of the leading authorities in laser vision correction and advanced cataract and refractive surgery, is the first eye care centre in North America to introduce the innovative LipiFlow® evaporative dry eye disease treatment system, which has received a medical device licence from Health Canada.

Evaporative dry eye is caused by a deficiency ...

TearScience Introduces LipiView and LipiFlow Devices at Canadian Ophthalmic Society Exhibition

MORRISVILE, N.C.–TearScience, Inc., a privately-held medical device company, today announced the product launch of its LipiView® Ocular Surface Interferometer and LipiFlow Thermal Pulsation medical devices in Canada. TearScience’s devices were designed to help eye care physicians address a root cause of evaporative dry eye, Meibomian Gland Dysfunction (MGD), which results in a lipid deficiency of the eye’s natural tear film. LipiView helps physicians visualize the eye’s natural tear film. LipiFlow ...

Tearscience’s LipiView Medical device wins medical design excellence award

LipiView Helps Eye Care Physicians Visualize Dry Eye Patients’ Tear Films

Morrisvile, N.C.,—May 31, 2011—TearScience, Inc., a privately-held medical device company, today announced that its LipiView® Ocular Surface Interferometer has received the Medical Design Excellence Award from UBM Canon. The LipiView provides eye care physicians with a new, in-office tear film procedure for dry eye patients, which takes less than 5 minutes.

“We are honored to receive this distinguished award,” said Tim Willis, chief ...

TearScience, Inc., a privately-held medical device company, today announced that it has appointed Jeff O’Hara as vice president of sales for North America.

In this role, O’Hara will direct the company’s U.S. and Canadian sales and customer service organizations. He will lead the sales team in providing TearScience’s advanced solutions to eye care practices to treat patients suffering from Evaporative Dry Eye disease and Meibomian Gland Dysfunction.

“Given Jeff’s broad experience in the medical device industry, he was the ideal candidate for ...

TearScience Raised the Largest 2010 Med Tech Venture Capital Funding in Southeast

MORRISVILLE, N.C.,—December 21, 2010—TearScience, Inc., a privately-held medical device company, today announced that it has received the Southeast Deal of the Year Venture Capital Transaction Award from Southeast BIO (SEBIO), a nonprofit organization that fosters the growth of the life sciences industry in the U.S. Southeastern region.  TearScience was recognized for having raised $44.5 million Series C financing in May, 2010.  TearScience’s C round investors included Essex Woodlands Health ...

MORRISVILE, N.C., —May 5, 2010—TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company’s existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.

“We are ...